Article
Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study.
Expert opinion on drug safety - 1 Mar 2018
Chamorro-de-Vega Esther, Gimenez-Manzorro Alvaro, Rodriguez-Gonzalez Carmen-Guadalupe, Escudero-Vilaplana Vicente, De Lorenzo-Pinto Ana, Iglesias-Peinado Irene, Herranz-Alonso Ana, Sanjurjo Saez Maria
Abstract excerpt
OBJECTIVE: To explore the effectiveness and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir (OBV/PTV/r+DSV) for 12 weeks without ribavirin in adults with chronic HCV genotype 1b infection and compensated cirrhosis. METHODS: Observational study of a prospective cohort of adult patients with HCV genotype 1b infection and compensated cirrhosis who received 12 weeks of OBV/PTV/r and DSV without ribavirin....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.